PDL BioPharma Earnings: Here’s Why Investors are Buying Shares Now
PDL BioPharma, Inc. (NASDAQ:PDLI) delivered a profit and beat Wall Street’s expectations, AND beat the revenue expectation. The revenue beat is a positive sign to shareholders seeking high growth out of the company. Shares are up 1.48%.
PDL BioPharma, Inc. Earnings Cheat Sheet
Results: Adjusted Earnings Per Share increased 19.23% to $0.62 in the quarter versus EPS of $0.52 in the year-earlier quarter.
Revenue: Rose 14.06% to $143.6 million from the year-earlier quarter.
Actual vs. Wall St. Expectations: PDL BioPharma, Inc. reported adjusted EPS income of $0.62 per share. By that measure, the company beat the mean analyst estimate of $0.54. It beat the average revenue estimate of $138.2 million.
Key Stats (on next page)…
Revenue increased 56.34% from $91.85 million in the previous quarter. EPS increased 72.22% from $0.36 in the previous quarter.
Looking Forward: Analysts have a neutral outlook for the company’s next-quarter performance. Over the past three months, the average estimate for next quarter’s earnings is a profit of $0.38 and has not changed. For the current year, the average estimate has moved up from a profit of $1.62 to a profit of $1.63 over the last ninety days.
Stocks with improving earnings metrics are worthy of your extra attention. In fact, “E = Earnings Are Increasing Quarter-Over-Quarter” is a core component of our CHEAT SHEET investing framework for this very reason. Don’t waste another minute – click here and get our CHEAT SHEET stock picks now.
(Company fundamentals provided by Xignite Financials. Email any earnings discrepancies to earnings [at] wallstcheatsheet.com)